ClinicalTrials.gg
CompletedNCT06326047Updated Sep 21, 2026

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

A Phase 2 interventional study of NNC0519-0130 and Placebo in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 110 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
299
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S — 25 open to participants now, 29 under way, 11 of them phase 3. Diabetes Mellitus, Type 2 · Novo Nordisk A/S.

Enrollment
171st of 428
299 · median 209
Started
2024
with 25 others
Phase 2
37 of 643
2 open now
Registered
596th of 643
by date

Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 171st largest by enrollment of the 428 interventional ones that give a count, is one of 26 that started in 2024, is one of 37 in phase 2, and was the 596th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

25 of the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female of non-, or male.
  • For United States (US) only: Female of childbearing potential using highly effective non-systemic methods of with low user-dependency and willingness to continue using it through-out the study or male.
  • Age 18-75 years (both inclusive) at the time of signing the .
  • Diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening.
  • Stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (SGLT2) inhibitor.
  • (HbA1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
  • (BMI) greater than or equal 23.0 kilograms per meter square (kg/m\^2).

Exclusion criteria

Exclusion Criteria:

  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
299 participants (actual)

Study arms

  • Experimental
    Dosing scheme A (NNC0519-0130)

    Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner.

    Drug: NNC0519-0130

  • Placebo comparator
    Dosing scheme A (Placebo)

    Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

    Drug: Placebo

  • Experimental
    Dosing scheme B (NNC0519-0130)

    Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner.

    Drug: NNC0519-0130

  • Placebo comparator
    Dosing scheme B (Placebo)

    Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

    Drug: Placebo

  • Experimental
    Dosing scheme C (NNC0519-0130)

    Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner.

    Drug: NNC0519-0130

  • Placebo comparator
    Dosing scheme C (Placebo)

    Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

    Drug: Placebo

  • Experimental
    Dosing scheme D (NNC0519-0130)

    Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner.

    Drug: NNC0519-0130

  • Placebo comparator
    Dosing scheme D (Placebo)

    Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

    Drug: Placebo

  • Experimental
    Dosing scheme E (NNC0519-0130)

    Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner.

    Drug: NNC0519-0130

  • Placebo comparator
    Dosing scheme E (Placebo)

    Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

    Drug: Placebo

  • Active comparator
    Dosing scheme F (tirzepatide)

    Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner.

    Drug: Trizepatide

Interventions

  • NNC0519-0130 will be administered subcutaneously.

  • DrugPlacebo

    Placebo will be administered subcutaneously.

  • DrugTrizepatide

    Trizepatide will be administered subcutaneously.

This study also gives Tirzepatide. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change in Glycated haemoglobin (HbA1c)

    Measured as percentage point (%-point)

    Time frame: From baseline (week 0) to 12 weeks on a given maintenance dose

Secondary outcomes

  1. Change in Glycated haemoglobin (HbA1c)

    Measured as percentage point (%-point)

    Time frame: From baseline (week 0) to end of treatment (week 36)

  2. Relative change in body weight

    Measured as percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 36)

  3. Change in body weight

    Measured as kilograms (kg)

    Time frame: From baseline (week 0) to end of treatment (week 36)

  4. Change in fasting plasma glucose (FPG)

    Measured as millimoles per liter (mmol/L)

    Time frame: From baseline (week 0) to 12 weeks on a given maintenance dose

  5. Continuous glucose monitoring (CGM): Change in time in range (TIR) 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))

    Measured as percentage point (%-point)

    Time frame: From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively

  6. Change in waist circumference

    Measured as centimeter (cm)

    Time frame: From baseline (week 0) to end of treatment (week 36)

  7. Change in systolic blood pressure (SBP)

    Measured as millimeters of mercury (mmHg)

    Time frame: From baseline (week 0) to end of treatment (week 36)

  8. Change in high sensitivity C-Reactive Protein (hsCRP)

    Measured as ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 36)

  9. Change in total cholesterol

    Measured as ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 36)

  10. Change in high-density lipoprotein (HDL) cholesterol

    Measured as ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 36)

  11. Change in low-density lipoprotein (LDL) cholesterol

    Measured as ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 36)

  12. Change in triglycerides

    Measured as ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 36)

  13. Number of adverse events

    Measured as number of events

    Time frame: From baseline (week 0) to end of study (week 40)

07

Study locations

110 sites
  • Velocity Clin Res-Chula Vista
    Chula Vista, California 91911, United States
  • Valley Research
    Fresno, California 93720, United States
  • 310 Clinical Research
    Inglewood, California 90301, United States
  • Velocity Clin Res San Diego
    La Mesa, California 91942, United States
  • First Valley Med Grp Lancaster
    Lancaster, California 93534, United States
  • Torrance Clin Res Inst, Inc.
    Lomita, California 90717, United States
  • Pacific Clinical Studies
    Los Alamitos, California 90720, United States
  • Velocity Clinical Research Westlake
    Los Angeles, California 90057, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • Artemis Insitute for Clin Res
    San Diego, California 92123, United States
  • Med Partners, Inc.
    Toluca Lake, California 91602, United States
  • UCLA Health Southbay Endocrine
    Torrance, California 90505, United States
  • University Clin Investigators
    Tustin, California 92780, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Innovative Research of W Florida Inc.
    Clearwater, Florida 33756, United States
  • Innovative Research of W FL
    Clearwater, Florida 33756, United States
  • International Research Associates, LLC_Miami
    Miami, Florida 33183, United States
  • Centricity Research
    Columbus, Georgia 31904, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • Methodist Medical Center of Illinois
    Peoria, Illinois 61603, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Centennial Medical Group
    Columbia, Maryland 21045, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • Endo And Metab Cons
    Rockville, Maryland 20852, United States
  • Clinvest Research
    Springfield, Missouri 65807, United States
  • Mercury Str Med Grp, PLLC
    Butte, Montana 59701, United States
  • Velocity Clinical Research Lincoln
    Lincoln, Nebraska 68510, United States
  • Excel Clinical Network
    Las Vegas, Nevada 89109, United States
  • Palm Research Center Inc-Vegas
    Las Vegas, Nevada 89148, United States
  • Velocity Clinical Research Binghamton
    Binghamton, New York 13905, United States
  • PharmQuest Life Sciences LLC
    Greensboro, North Carolina 27408, United States
  • Accellacare Wilmington
    Wilmington, North Carolina 28401, United States
  • Diab & Endo Assoc of Stark Co
    Canton, Ohio 44718, United States
  • Velocity Clin Res_Cincinnati
    Cincinnati, Ohio 45242, United States
  • Velocity Clinical Research Springdale
    Cincinnati, Ohio 45246, United States
  • Providence Health Partners Ctr
    Dayton, Ohio 45439, United States
  • Advanced Med Res Maumee
    Maumee, Ohio 43537, United States
  • Velocity Clin Res Grants Pass
    Grants Pass, Oregon 97527, United States
  • Tristar Clin Investigations, PC
    Philadelphia, Pennsylvania 19114, United States
  • Preferred Primary Care Physicians Inc.
    Pittsburgh, Pennsylvania 15243, United States
  • Preferred Primary Care Physicians, Inc.
    Uniontown, Pennsylvania 15401, United States
  • Velocity Clinical Research Abilene
    Abilene, Texas 79606, United States
  • Velocity Clin Res Austin
    Austin, Texas 78759, United States
  • Velocity Clinical Res-Dallas
    Dallas, Texas 75230, United States
  • Zenos Clinical research
    Dallas, Texas 75230, United States
  • UT Southwestern Med Center
    Dallas, Texas 75390, United States
  • Care United Research, LLC
    Forney, Texas 75126, United States
  • Endocrine Associates Houston
    Houston, Texas 77004, United States
  • Biopharma Informatic_Houston
    Houston, Texas 77043, United States
  • Tekton Research
    Irving, Texas 75039, United States
  • Epic Clinical Research
    Lewisville, Texas 75057, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • Burke Internal Medicine & Research
    Burke, Virginia 22015, United States
  • TPMG Clinical Research
    Newport News, Virginia 23606, United States
  • Campbelltown Hospital
    Campbelltown, New South Wales 2560, Australia
  • Macquarie University - Clinical Trials Unit
    Macquarie Park, New South Wales 2109, Australia
  • Royal North Shore Hospital
    St Leonards, New South Wales 2065, Australia
  • Roger Chih Yu Chen
    Sydney, New South Wales 2148, Australia
  • Western Endocrine Blacktown
    Sydney, New South Wales 2148, Australia
  • Illawarra Diabetes Service Clinical Trials & Research Unit
    Wollongong, New South Wales 2500, Australia
  • University of Sunshine Coast - Vitality Village
    Birtinya, Queensland 4575, Australia
  • Logan Hospital
    Meadowbrook, Queensland 4131, Australia
  • Southern Adelaide Diabetes & Endocrine Services
    Oaklands Park, South Australia 5046, Australia
  • Eastern Clinical Research Unit Box Hill
    Box Hill, Victoria 3128, Australia
  • Emeritus Research Melbourne
    Camberwell, Victoria 3124, Australia
  • Austin Health, Metabolic Disorders Centre
    Heidelberg Heights, Victoria 3081, Australia
  • The Royal Melbourne Hospital - Diabetes & Endocrinology Department
    Parkville, Victoria 3050, Australia
  • The Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Fremantle Hospital
    Fremantle, Western Australia 6160, Australia
  • OCT Research ULC (dba Okanagan Clinical Trials)
    Kelowna, British Columbia V1Y 1Z9, Canada
  • OCT Research ULC (dba Okanagan Clinical Trials)
    Richmond, British Columbia V6V 2L1, Canada
  • Cook Street Medical Clinic
    Victoria, British Columbia V8V 4A1, Canada
  • G.A. Research Associates Ltd.
    Moncton, New Brunswick E1G 1A7, Canada
  • Nova Scotia Hlth Halifax
    Halifax, Nova Scotia B3H 1V7, Canada
  • Centricity Research Barrie
    Barrie, Ontario L4N 7L3, Canada
  • Wharton Medical Clinic Clinical Trials (Hamilton)
    Hamilton, Ontario L8L 5G8, Canada
  • London Road Diagnostic Clinic and Medical Centre
    Sarnia, Ontario N7T 4X3, Canada
  • Centricity Research Toronto
    Toronto, Ontario M4G 3E8, Canada
  • Albion Finch Medical Centre
    Toronto, Ontario M9V 4B4, Canada
  • Centricity Research Quebec City
    Lévis, Quebec G6W 0M5, Canada
  • Centricity Research Mirabel
    Mirabel, Quebec J7J 2K8, Canada
  • Recherche GCP Research
    Montreal, Quebec H1Y 3H5, Canada
  • Centricity Research Ville St. Laurent VSL
    Saint-Laurent, Quebec H4T 1Z9, Canada
  • Diex Recherche Quebec
    Québec, G1V 4T3, Canada
  • Life Care Hospital and Research Centre
    Bangalore, Karnataka 560092, India
  • Amrita Institute Of Medical Sciences & Research Centre
    Kochi, Kerala 682041, India
  • TOTALL Diabetes Hormone Institute
    Indore, Madhya Pradesh 452010, India
  • Seth GS Medical College & KEM Hospital
    Mumbai, Maharashtra 400012, India
  • Chellaram Diabetes Institute
    Pune, Maharashtra 411021, India
  • Diabetes, Thyroid and Endocrine Centre
    Jaipur, Rajasthan 302006, India
  • Christian Medical College Hospital, Vellore
    Vellore, Tamil Nadu 632004, India
  • Diabetes Research Center, Hyderabad
    Hyderabad, Telangana 500082, India
  • MS Ramaiah
    Bengaluru, 560054, India
  • Lady Hardinge Medical College
    New Delhi, 110001, India
  • Tokuyama clinic_Diabetic internal medicine
    Chiba, 261-0004, Japan
  • Soka Sugiura Internal Medicine Clinic
    Soka-shi, Saitama, 340-0015, Japan
  • Tokyo-Eki Center-building Clinic_Internal Medicine
    Tokyo, 103-0027, Japan
  • Fukuwa Clinic_Internal Medicine
    Tokyo, 104-0031, Japan
  • Fukuwa Clinic
    Tokyo, 104-0031, Japan

Showing the first 100 of 110 sites across 7 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Sep 2025, 18 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 18 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2024
First posted
Mar 22, 2024
StartActual
Mar 18, 2024
Primary completionActual
Sep 19, 2025
CompletionActual
Oct 13, 2025
Results delay requested
Sep 18, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06326047
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 22, 2024
Start date
Mar 18, 2024
Primary completion
Sep 19, 2025
Completion
Oct 13, 2025
Last update
Sep 21, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NNC0519-0130

Start the discussion